Anzeige
Meldung des Tages: Wegweisende News: NurExone – Pionier der regenerativen neuronalen Medizin!

Coya Therapeutics News

Aktie
WKN:  A3DZRY ISIN:  US22407B1089 US-Symbol:  COYA Branche:  Biotechnologie Land:  USA
5,05 $
+0,17 $
+3,48%
4,2730 € 25.02.26
Depot/Watchlist
Marktkapitalisierung *
67,56 Mio. €
Streubesitz
71,56%
KGV
-4,55
Index-Zuordnung
-

Coya Therapeutics News

29.09.25 - PR Newswire
Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal Dementia
Coya Therapeutics Announces Completion of Patient Enrollment of an Investigator-​Initiated, Open-​Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients ...
22.09.25 - PR Newswire
Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis
Coya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral Sclerosis PR Newswire
16.09.25 - PR Newswire
Coya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical Animal Inflammation Model
Coya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-​inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical ...
04.09.25 - PR Newswire
Coya Therapeutics' COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated Trial
Coya Therapeutics' COYA 302 ALS Trial Accepted by NEALS as a NEALS-​Affiliated Trial PR Newswire
03.09.25 - PR Newswire
Coya Therapeutics to Participate at Upcoming September Investor Conferences
Coya Therapeutics to Participate at Upcoming September Investor Conferences PR Newswire
25.08.25 - PR Newswire
Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Coya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) PR Newswire
12.08.25 - PR Newswire
Coya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update
Coya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate Update PR Newswire

Newssuche

Videos

newspaper
25.02.26
So beeinflussen Margins DEIN Trading
Börsentäglich ab 18 Uhr Feierabend-​Trading Live. Teilnahme kostenlos mit diesem Link ... Mehr »